Risks of cancellations or reductions in contracted projects and shortages of equipment and personnel
First written in FY2018. 9 of 17 entries say "Materialised", first in FY2019-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026MaterialisedAnnual report
「Revenue declined in relation to TEIJIN (帝人株式会社) because milestones were deferred to the following fiscal year and because, in contract work for general customers, one-off revenue from a specific customer recorded in the previous fiscal year fell away, among other factors.」
In the contract business, milestones were deferred to a subsequent period and one-off revenue fell away, resulting in a 23.5% decline in revenue from the previous fiscal year. - FY2025MaterialisedAnnual report
「In the current fiscal year, revenue declined compared with the previous fiscal year, when milestone and contract revenue was generated in connection with the launch of 帝人リジェネット株式会社, due to delays in scheduled milestones and a decrease in contract work. In addition, the milestones scheduled for the current fiscal year were also delayed.」
The risk of delays in contract projects and milestones actually materialized, resulting in lower revenue related to TEIJIN and lower contract business revenue. - FY2024RestatedAnnual report
「Contract work may be cancelled or reduced in scope due to development progress, changes in the policies of contracting parties and other factors.」
The risk of cancellations and downsizing due to changes in the policies of contracting parties continues to be disclosed, with close coordination with contracting parties serving as a response measure. - FY2023-Q3MaterialisedAnnual report
「Revenue from the regenerative medicine contract business for the cumulative third quarter was ¥262.151 million, down 15.2% year on year. Although contract work from the parent company, TEIJIN LIMITED (hereinafter, "TEIJIN"), increased, the acquisition of new projects was delayed by the effects of COVID-19 and other factors, resulting in lower revenue than in the same period of the previous year.」
In the regenerative medicine contract business, delays in acquiring new projects due to the effects of COVID-19 and other factors actually occurred, resulting in a 15.2% year-on-year decline in revenue. - FY2022-Q2MaterialisedAnnual report
「Meanwhile, revenue overall declined from the same period of the previous year because some projects were delayed or their schedules changed.」
In the regenerative medicine contract business, delays and schedule changes actually occurred in some projects, resulting in lower revenue. - FY2022-Q1MitigatedAnnual report
「As some clinical trials and other activities resumed at companies and academic institutions where development had been delayed by the effects of COVID-19, contract work progressed on multiple projects.」
The impact of development stagnation and execution delays for contract projects was partly reduced as companies and academic institutions resumed some clinical trials and other activities, and work progressed on multiple projects. - FY2021-Q3MitigatedAnnual report
「From the third quarter onward, there was a pronounced trend among companies and academic institutions toward resuming development, including clinical trials. Contracts for the next development stage were executed for multiple projects, providing visibility into revenue generation in the fourth quarter.」
The risk of development stagnation and delays in executing contracts for contract projects was partly reduced by customers resuming development, contracts being executed for multiple projects, and the outlook for revenue generation in the fourth quarter. - FY2021-Q2MitigatedAnnual report
「However, recently there has been a pronounced trend among customers toward resuming development, and discussions on executing contracts for the next development stage are progressing. The Company will continue discussions with customers aimed at resuming development and executing contracts while taking the effects of COVID-19 into account, and will seek to recover revenue by focusing on projects that can be carried out even amid the pandemic.」
Although development stagnation and execution delays for contract projects caused by the pandemic remain, customer development is resuming and discussions on executing contracts are progressing, with the Company seeking to recover revenue by focusing on viable projects. - FY2021-Q1WorsenedAnnual report
「Revenue from the regenerative medicine contract business for the cumulative first quarter was ¥73.724 million, down 40.6% year on year. At medical institutions and companies commissioning work that were significantly affected by COVID-19, development not only stalled, but clinical trial starts and technology transfers overseas were also delayed, resulting in a substantial decline in revenue from the same period of the previous year.」
In addition to the existing delays in contracts and execution for contract projects, development stagnation caused by COVID-19 and delays in starting clinical trials and transferring technology overseas occurred, resulting in a 40.6% year-on-year decline in contract business revenue. - FY2020MaterialisedAnnual report
「Revenue declined slightly year on year, partly because setting conditions before the start of work and resolving issues that arose after work began took longer than expected.」
In the regenerative medicine contract business, setting conditions before the start of work and resolving issues after commencement took longer than expected, resulting in revenue of ¥813.450 million, down 2.7% year on year. - FY2020-Q3MaterialisedAnnual report
「Projects have taken longer than expected to begin or execute, and revenue was ¥466.985 million, down 1.4% year on year.」
In the regenerative medicine contract business, delays actually occurred in the start and execution of projects, resulting in lower revenue. - FY2020-Q2MaterialisedAnnual report
「Some projects took longer than expected to begin or execute, and the timing of revenue recognition was delayed beyond schedule for some projects. As a result, revenue increased only slightly compared with the same period of the previous year.」
In the regenerative medicine contract business, delays actually occurred in the start and execution of projects, together with corresponding delays in the timing of revenue recognition. - FY2019-Q3MaterialisedAnnual report
「However, execution is behind schedule against the target revenue for reasons including that determining detailed specifications and executing contracts have taken longer than expected.」
In the regenerative medicine contract business, determining detailed specifications and executing contracts took longer than expected, resulting in an actual delay in execution against target revenue. - FY2019-Q1MaterialisedAnnual report
「Although the number of development and manufacturing contract projects for regenerative medicine products increased as a result of customer development activities targeting companies and academia, revenue declined from the same period of the previous year because contract renewals and agreement on the scope of work with some customers took time, and the receipt of consideration such as milestone payments was delayed.」
Although there was no cancellation or downsizing of contract projects per se, delays actually occurred in renewing contracts and agreeing on the scope of work with certain customers, as well as in receiving consideration such as milestone payments. - FY2018First statedAnnual report
「Depending on development progress and changes in the policies of contracting parties, among other factors, contract work may be cancelled or reduced in scope. In addition, the equipment and personnel available to the Company may be insufficient to respond adequately and meet the needs of developers.」
The potential cancellation or downsizing of projects due to changes in the policies of contracting parties, and insufficient capacity using the Company's own equipment and personnel, were identified as new risks accompanying the expansion of the regenerative medicine contract business.